Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

• IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing
• IMM-BCP-01 currently in Phase 1b clinical testing with topline data expected in 2H 2022

Excerpt from the Press Release:

EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently in Phase 1b clinical testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5 and BA.2.

IMM-BCP-01 is a three-antibody cocktail with each antibody having a different mechanism of action. IMM20190 binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop preventing binding to ACE2. IMM20184 and IMM20253 neutralized live BA.2 Omicron variant in in vitro testing as well as pseudoviruses corresponding to the BA.2.12.1 and BA.4/.5 subvariants. In particular, IMM20253 neutralized the virus through an ACE2-independent mechanism that differs from the neutralization mechanisms used by current or past antibodies approved for clinical use. Data recently published in Science Immunology provides a mechanistic basis for how IMM20253 binding, which is conserved across all variants to date including Omicron and its sub-lineages, neutralized SARS-CoV-2.

“We are pleased that IMM-BCP-01 retains effectiveness against the currently dominant BA.4/.5 and BA.2.12.1 subvariants,” stated Purnanand Sarma, PhD, President & CEO of Immunome.

Click the button below to read the entire Press Release:

Continue Reading The Press Release